These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8340363)

  • 21. Inhibition of HIV-1 protease: the rigidity perspective.
    Heal JW; Jimenez-Roldan JE; Wells SA; Freedman RB; Römer RA
    Bioinformatics; 2012 Feb; 28(3):350-7. PubMed ID: 22291339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.
    Ghosh AK; Thompson WJ; Fitzgerald PM; Culberson JC; Axel MG; McKee SP; Huff JR; Anderson PS
    J Med Chem; 1994 Aug; 37(16):2506-8. PubMed ID: 8057296
    [No Abstract]   [Full Text] [Related]  

  • 26. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
    Lange-Savage G; Berchtold H; Liesum A; Budt KH; Peyman A; Knolle J; Sedlacek J; Fabry M; Hilgenfeld R
    Eur J Biochem; 1997 Sep; 248(2):313-22. PubMed ID: 9346283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
    Janakiraman MN; Watenpaugh KD; Tomich PK; Chong KT; Turner SR; Tommasi RA; Thaisrivongs S; Strohbach JW
    Bioorg Med Chem Lett; 1998 May; 8(10):1237-42. PubMed ID: 9871742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir.
    Das A; Rao DR; Hosur MV
    Protein Pept Lett; 2007; 14(6):565-8. PubMed ID: 17627597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculations.
    McCarrick MA; Kollman PA
    J Comput Aided Mol Des; 1999 Mar; 13(2):109-21. PubMed ID: 10091118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
    Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
    Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.
    Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J
    Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of tight-binding human immunodeficiency virus type 1 protease inhibitors.
    Vacca JP
    Methods Enzymol; 1994; 241():311-34. PubMed ID: 7854186
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity.
    Thaisrivongs S; Tomasselli AG; Moon JB; Hui J; McQuade TJ; Turner SR; Strohbach JW; Howe WJ; Tarpley WG; Heinrikson RL
    J Med Chem; 1991 Aug; 34(8):2344-56. PubMed ID: 1875334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based inhibitors of HIV-1 protease.
    Wlodawer A; Erickson JW
    Annu Rev Biochem; 1993; 62():543-85. PubMed ID: 8352596
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhibitors of HIV protease: unique non-peptide active site templates.
    Tait BD; Domagala J; Ellsworth EL; Ferguson D; Gajda C; Hupe D; Lunney EA; Tummino PJ
    J Mol Recognit; 1996; 9(2):139-42. PubMed ID: 8877805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease.
    Nalam MN; Peeters A; Jonckers TH; Dierynck I; Schiffer CA
    J Virol; 2007 Sep; 81(17):9512-8. PubMed ID: 17596316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease.
    Rutenber EE; De Voss JJ; Hoffman L; Stroud RM; Lee KH; Alvarez J; McPhee F; Craik C; Ortiz de Montellano PR
    Bioorg Med Chem; 1997 Jul; 5(7):1311-20. PubMed ID: 9377091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state.
    Hornak V; Okur A; Rizzo RC; Simmerling C
    J Am Chem Soc; 2006 Mar; 128(9):2812-3. PubMed ID: 16506755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.
    Thaisrivongs S; Tomich PK; Watenpaugh KD; Chong KT; Howe WJ; Yang CP; Strohbach JW; Turner SR; McGrath JP; Bohanon MJ
    J Med Chem; 1994 Sep; 37(20):3200-4. PubMed ID: 7932546
    [No Abstract]   [Full Text] [Related]  

  • 40. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
    Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.